242 related articles for article (PubMed ID: 11099709)
1. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group.
Liu C; Blumhardt LD
J Neurol Sci; 2000 Dec; 181(1-2):33-7. PubMed ID: 11099709
[TBL] [Abstract][Full Text] [Related]
2. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
Liu C; Blumhardt LD
J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):450-7. PubMed ID: 10727480
[TBL] [Abstract][Full Text] [Related]
3. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves.
Liu C; Blumhardt LD
J Neurol Neurosurg Psychiatry; 1999 Oct; 67(4):451-6. PubMed ID: 10486390
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
5. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Johnson KP; Brooks BR; Ford CC; Goodman AD; Lisak RP; Myers LW; Pruitt AA; Rizzo MA; Rose JW; Weiner LP; Wolinsky JS
Mult Scler; 2003 Dec; 9(6):585-91. PubMed ID: 14664471
[TBL] [Abstract][Full Text] [Related]
7. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
Miller A; Spada V; Beerkircher D; Kreitman RR
Mult Scler; 2008 May; 14(4):494-9. PubMed ID: 18208875
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
[TBL] [Abstract][Full Text] [Related]
9. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.
Ford CC; Johnson KP; Lisak RP; Panitch HS; Shifronis G; Wolinsky JS;
Mult Scler; 2006 Jun; 12(3):309-20. PubMed ID: 16764344
[TBL] [Abstract][Full Text] [Related]
10. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
11. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
[TBL] [Abstract][Full Text] [Related]
12. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
15. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.
Ford C; Goodman AD; Johnson K; Kachuck N; Lindsey JW; Lisak R; Luzzio C; Myers L; Panitch H; Preiningerova J; Pruitt A; Rose J; Rus H; Wolinsky J
Mult Scler; 2010 Mar; 16(3):342-50. PubMed ID: 20106943
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Harrison DM; Gladstone DE; Hammond E; Cheng J; Jones RJ; Brodsky RA; Kerr D; McArthur JC; Kaplin A
Mult Scler; 2012 Feb; 18(2):202-9. PubMed ID: 21865410
[TBL] [Abstract][Full Text] [Related]
17. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
Flechter S; Vardi J; Pollak L; Rabey JM
J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
[TBL] [Abstract][Full Text] [Related]
18. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
19. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]